BMC Medical Genetics | |
Association between UCP2 A55V polymorphism and risk of cardiovascular events in patients with multi-vessel coronary arterial disease | |
Whady A Hueb1  Alexandre C Pereira1  José Eduardo Krieger1  Noely E Ferreira1  Luisa S Sugaya1  Paulo CJL Santos1  Luciana Gioli-Pereira1  | |
[1] Heart Institute (InCor), Sao Paulo University Medical School, Av. Dr. Enéas de Carvalho Aguiar, 44 Cerqueira César, São Paulo - SP, 05403-000, Brazil | |
关键词: Diabetes; Coronary artery disease; A55V polymorphism; UCP2; | |
Others : 1177713 DOI : 10.1186/1471-2350-14-40 |
|
received in 2011-11-17, accepted in 2013-03-18, 发布年份 2013 | |
【 摘 要 】
Background
UCP2 (uncoupling protein 2) plays an important role in cardiovascular diseases and recent studies have suggested that the A55V polymorphism can cause UCP2 dysfunction. The main aim was to investigate the association of A55V polymorphism with cardiovascular events in a group of 611 patients enrolled in the Medical, Angioplasty or Surgery Study II (MASS II), a randomized trial comparing treatments for patients with coronary artery disease and preserved left ventricular function.
Methods
The participants of the MASS II were genotyped for the A55V polymorphism using allele-specific PCR assay. Survival curves were calculated with the Kaplan–Meier method and evaluated with the log-rank statistic. The relationship between baseline variables and the composite end-point of cardiac death, acute myocardial infarction (AMI), refractory angina requiring revascularization and cerebrovascular accident were assessed using a Cox proportional hazards survival model.
Results
There were no significant differences for baseline variables according genotypes. After 2 years of follow-up, dysglycemic patients harboring the VV genotype had higher occurrence of AMI (p=0.026), Death+AMI (p=0.033), new revascularization intervention (p=0.009) and combined events (p=0.037) as compared with patients carrying other genotypes. This association was not evident in normoglycemic patients.
Conclusions
These findings support the hypothesis that A55V polymorphism is associated with UCP2 functional alterations that increase the risk of cardiovascular events in patients with previous coronary artery disease and dysglycemia.
【 授权许可】
2013 Gioli-Pereira et al.; licensee BioMed Central Ltd.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150504022131832.pdf | 271KB | download | |
Figure 1. | 32KB | Image | download |
【 图 表 】
Figure 1.
【 参考文献 】
- [1]Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
- [2]Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140-2144.
- [3]Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
- [4]Blanc J, Alves-Guerra MC, Esposito B, Rousset S, Gourdy P, Ricquier D, Tedgui A, Miroux B, Mallat Z: Protective role of uncoupling protein 2 in atherosclerosis. Circulation 2003, 107:388-390.
- [5]Cheurfa N, Dubois-Laforgue D, Ferrarezi DA, Reis AF, Brenner GM, Bouche C, Le Feuvre C, Fumeron F, Timsit J, Marre M, Velho G: The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men. Diabetes 2008, 57:1063-1068.
- [6]McLeod CJ, Aziz A, Hoyt RF Jr, McCoy JP Jr, Sack MN: Uncoupling proteins 2 and 3 function in concert to augment tolerance to cardiac ischemia. J Biol Chem 2005, 280:33470-33476.
- [7]Teshima Y, Akao M, Jones SP, Marban E: Uncoupling protein-2 overexpression inhibits mitochondrial death pathway in cardiomyocytes. Circ Res 2003, 93:192-200.
- [8]Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, Miroux B, Couplan E, Alves-Guerra MC, Goubern M, Surwit R: Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 2000, 26:435-439.
- [9]Klannemark M, Orho M, Groop L: No relationship between identified variants in the uncoupling protein 2 gene and energy expenditure. Eur J Endocrinol 1998, 139:217-223.
- [10]Cha MH, Kim IC, Kim KS, Kang BK, Choi SM, Yoon Y: Association of UCP2 and UCP3 gene polymorphisms with serum high-density lipoprotein cholesterol among Korean women. Metabolism 2007, 56:806-813.
- [11]Rance KA, Johnstone AM, Murison S, Duncan JS, Wood SG, Speakman JR: Plasma leptin levels are related to body composition, sex, insulin levels and the A55V polymorphism of the UCP2 gene. Int J Obes (Lond) 2007, 31:1311-1318.
- [12]Astrup A, Toubro S, Dalgaard LT, Urhammer SA, Sorensen TI, Pedersen O: Impact of the v/v 55 polymorphism of the uncoupling protein 2 gene on 24-h energy expenditure and substrate oxidation. Int J Obes Relat Metab Disord 1999, 23:1030-1034.
- [13]Yu X, Jacobs DR Jr, Schreiner PJ, Gross MD, Steffes MW, Fornage M: The uncoupling protein 2 Ala55Val polymorphism is associated with diabetes mellitus: the CARDIA study. Clin Chem 2005, 51:1451-1456.
- [14]Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA: Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007, 115:1082-1089.
- [15]Hueb W, Soares PR, Gersh BJ, Cesar LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JA: The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 2004, 43:1743-1751.
- [16]Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
- [17]Myakishev MV, Khripin Y, Hu S, Hamer DH: High-throughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers. Genome Res 2001, 11:163-169.
- [18]Sesti G, Cardellini M, Marini MA, Frontoni S, D’Adamo M, Del Guerra S, Lauro D, De Nicolais P, Sbraccia P, Del Prato S: A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 2003, 52:1280-1283.
- [19]D’Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, Andreozzi F, Sciacqua A, Lauro D, Sbraccia P, Federici M: The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. Diabetes 2004, 53:1905-1910.
- [20]Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997, 15:269-272.
- [21]Dhamrait SS, Stephens JW, Cooper JA, Acharya J, Mani AR, Moore K, Miller GJ, Humphries SE, Hurel SJ, Montgomery HE: Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J 2004, 25:468-475.
- [22]Dalgaard LT: Genetic Variance in Uncoupling Protein 2 in Relation to Obesity, Type 2 Diabetes, and Related Metabolic Traits: Focus on the Functional -866G>A Promoter Variant (rs659366). J Obes 2011, 2011:340241.
- [23]Beitelshees AL, Finck BN, Leone TC, Cresci S, Wu J, Province MA, Fabbrini E, Kirk E, Zineh I, Klein S: Interaction between the UCP2–866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes. Pharmacogenet Genomics 2010, 20:231-238.
- [24]Xu K, Zhang M, Cui D, Fu Y, Qian L, Gu R, Wang M, Shen C, Yu R, Yang T: UCP2–866G/A and Ala55Val, and UCP3–55C/T polymorphisms in association with type 2 diabetes susceptibility: a meta-analysis study. Diabetologia 2011, 54:2315-2324.